Concentra Announces Fourth Quarter and Full Year 2024 Results and Closing of Nova Medical Centers Acquisition

ADDISON, Texas--(BUSINESS WIRE)--March 03, 2025-- 

Concentra Group Holdings Parent, Inc. ("Concentra," the "Company," "we," "us," or "our") $(CON)$, the nation's largest provider of occupational health services, today announced results for its fourth quarter and full year ended December 31, 2024. Additionally, the Company announced the closing of the transaction to acquire U.S. Occmed Holdings, LLC ("Nova Medical Centers" or "Nova"), an occupational health services company with 67 medical centers based in Houston, Texas.

"Concentra had a successful 2024 -- a year marked by change with our IPO and separation from Select Medical. We made significant progress on key strategic initiatives and maintained our emphasis on the delivery of high-quality patient care. Our ability to execute on our objectives and the tireless efforts of our colleagues contributed to our favorable 2024 financial outcomes. I am confident in our ability to continue to deliver strong results in 2025," said Keith Newton, Chief Executive Officer of Concentra.

Matt DiCanio, Concentra's President & Chief Financial Officer added, "The impact of our expanded footprint in new and existing geographies during 2024 meant it was easier than ever for our clients to do business with us -- and patients benefited as demonstrated in high patient satisfaction scores. With a sustained focus on our development pipeline including the integration of recently acquired Nova Medical Centers, we are well positioned for continued growth in 2025."

Fourth Quarter 2024 Highlights

For the fourth quarter ended December 31, 2024 and 2023:

   -- 
 Revenue of $465.0 million, an increase of 5.5% from $440.7 million in 
      Q4 2023 
 
 
   -- 
 Net Income of $22.8 million, and earnings per share of $0.17 in Q4 
      2024 
 
 
   -- 
 Adjusted EBITDA of $77.5 million, an increase of 13.6% from $68.3 
      million in Q4 2023 
 
 
   -- 
 Cash balance at year end of $183.3 million and net leverage of 3.46x 
 
 
   -- 
 Patient Visits of 2,994,988, or 46,797 Visits per Day, a decrease in 
      Visits per Day of 2.1% from Q4 2023 
 
 
   -- 
 Revenue per Visit of $145.08, an increase of 5.8% from $137.15 in Q4 
      2023 
 
 
   -- 
 Total occupational health centers of 552, compared to 544 at the end of 
      Q4 2023 
 
 
   -- 
 Total onsite health clinics of 157, compared to 150 at the end of Q4 
      2023 
 

Fourth Quarter 2024 Financial Overview

For the fourth quarter ended December 31, 2024, revenue increased 5.5% to $465.0 million, compared to $440.7 million for the same quarter, prior year. Income from operations increased 19.8% to $59.1 million for the fourth quarter ended December 31, 2024, compared to $49.3 million for the same quarter, prior year. Net income was $22.8 million and earnings per common share was $0.17 for the fourth quarter ended December 31, 2024. Adjusted EBITDA increased 13.6% to $77.5 million for the fourth quarter ended December 31, 2024, compared to $68.3 million for the same quarter, prior year. The definition of Adjusted EBITDA and a reconciliation of net income to Adjusted EBITDA are presented in table X of this release.

Year to Date December 31, 2024 Financial Overview

For the year ended December 31, 2024, revenue increased 3.4% to $1,900.2 million, compared to $1,838.1 million for the same period, prior year. Income from operations increased 6.0% to $304.8 million for the year ended December 31, 2024, compared to $287.6 million for the same period, prior year. Net income was $171.9 million and earnings per common share was $1.46 for the year ended December 31, 2024. Adjusted EBITDA increased 4.3% to $376.9 million for the year ended December 31, 2024, compared to $361.3 million for the same period, prior year. The definition of Adjusted EBITDA and a reconciliation of net income to Adjusted EBITDA are presented in table X of this release.

Balance Sheet

As of December 31, 2024, our balance sheet reflected cash of $183.3 million, total debt of $1,479.0 million and total assets of $2,521.2 million.

Cash Flow

Cash flows provided by operating activities in the fourth quarter ended December 31, 2024 totaled $93.7 million compared to $76.2 million for the same quarter, prior year. During the fourth quarter ended December 31, 2024, capital expenditures totaled $16.7 million, excluding acquisitions.

Nova Acquisition Closing

Effective March 1, 2025, the Company acquired Nova Medical Centers for a purchase price of $265 million, subject to adjustment in accordance with the terms and conditions set forth in the equity purchase agreement.

Concentra is just beginning the process of integrating Nova Medical Centers into its portfolio of medical centers, with the acquisition helping to strengthen the delivery of quality care and exceptional service through greater access, while also resulting in accelerated innovation and enhanced outcomes for patients, customers and employers. With the addition of Nova Medical Centers, we have over 80 years of combined history supporting and providing occupational health services and have expanded to more than 770 occupational health centers and onsite health clinics at employer worksites located across the country.

The transaction was financed using a combination $102.1 million of new debt financing under the Credit Agreement, $50.0 million of available borrowing capacity under our existing Revolving Credit Facility, and the remaining with cash on hand.

Debt Financing

As part of the funding of the Nova transaction, Concentra has concurrently re-priced its Credit Facilities. Inclusive of the $102.1 million add-on, the Term Loan B due 2031 now has a balance of $950.0 million. The Term Loan interest rate has been reduced from Term SOFR plus 2.25% down to Term SOFR plus 2.00%, subject to a leverage-based pricing grid including a 25-basis point step down at a net leverage ratio of <=3.25x. And in conjunction with the $50.0 million draw on the revolver to partially fund the Nova transaction, the Revolving Credit Facility has been increased from $400.0 million to $450.0 million. The interest rate for the Revolving Credit Facility has been reduced from Term SOFR plus 2.50% to Term SOFR plus 2.00%, subject to a leverage-based pricing grid.

Giving effect to the Nova acquisition and debt-refinancing, Concentra's pro forma net leverage ratio post-transaction is 3.9x, which is in compliance with the financial covenant under the credit agreement. The Company is targeting a net leverage ratio of approximately 3.0x within 18-24 months.

2025 Business Outlook

Concentra's strong business performance in 2024 positions the Company well for continued growth as reflected in its 2025 financial guidance. For 2025, giving effect to the acquisition of Nova Medical Centers, Concentra expects to deliver the following results:

   -- 
 Revenue of approximately $2.1 billion 
 
 
   -- 
 Adjusted EBITDA in the range of $410 million to $425 million 
 
 
   -- 
 Capital expenditures in the range of $80 million to $90 million 
 
 
   -- 
 Net leverage ratio of approximately 3.5x 
 

A reconciliation of full year 2025 Adjusted EBITDA expectations to net income is presented in table XI of this release.

Dividend

On February 28, 2025, the Board of Directors declared a cash dividend of $0.0625 per share. The dividend will be payable April 1, 2025, to stockholders of record as of the close of business on March 18, 2025.

There is no assurance that future dividends will be declared. The declaration and payment of dividends in the future are at the discretion of the Board of Directors after taking into account various factors, including, but not limited to, the Company's financial condition, operating results, available cash and current and anticipated cash needs, the terms of indebtedness, and other factors the Board of Directors may deem to be relevant.

Company Overview

Concentra is the largest provider of occupational health services in the United States by number of locations, with the mission of improving the health of America's workforce, one patient at a time. Our approximately 11,000 colleagues and affiliated physicians and clinicians support the delivery of an extensive suite of services, including occupational and consumer health services and other direct-to-employer care. We support the care of approximately 50,000 patients each day on average across 45 states at our 552 occupational health centers, 157 onsite health clinics at employer worksites, and Concentra Telemed as of December 31, 2024.

Conference Call

Concentra will host a conference call regarding its fourth quarter results and its business outlook on Tuesday, March 4, 2025, at 9:00 am ET. The conference call will be a live webcast and can be accessed at Concentra Group Holdings Parent, Inc.'s website at www.concentra.com and a replay of the webcast will be available shortly after the call through the same link.

For listeners wishing to dial-in via telephone, or participate in the question and answer session, you may pre-register for the call at Concentra Earnings Call Registration to obtain your dial-in number and unique passcode.

* * * * *

Certain statements contained herein that are not descriptions of historical facts are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995), including statements related to Concentra's 2025 and long-term business outlook. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements due to factors including the following:

   -- 
 The frequency of work-related injuries and illnesses; 
 
 
   -- 
 The adverse changes to our relationships with employer customers, 
      third-party payors, workers' compensation provider networks or employer 
      services networks; 
 
 
   -- 
 Changes to regulations, new interpretations of existing regulations, or 
      violations of regulations; 
 
 
   -- 
 Cost containment initiatives or state fee schedule changes undertaken 
      by state workers' compensation boards or commissions and other 
      third-party payors; 
 
 
   -- 
 Our ability to realize reimbursement increases at rates sufficient to 
      keep pace with the inflation of our costs; 
 
 
   -- 
 Labor shortages, increased employee turnover or costs, and union 
      activity could significantly increase our operating costs; 
 
 
   -- 
 Our ability to compete effectively with other occupational health 
      centers, onsite health clinics at employer worksites, and healthcare 
      providers; 
 
 
   -- 
 A security breach of our, or our third-party vendors', information 
      technology systems which may cause a violation of HIPAA and subject us to 
      potential legal and reputational harm; 
 
 
   -- 
 Negative publicity which can result in increased governmental and 
      regulatory scrutiny and possibly adverse regulatory changes; 
 
 
   -- 
 Significant legal actions could subject us to substantial uninsured 
      liabilities; 
 
 
   -- 
 Litigation and other legal and regulatory proceedings in the course of 
      our business that could adversely affect our business and financial 
      statements; 
 
 
   -- 
 Insurance coverage may not be sufficient to cover losses we may incur; 
 
 
   -- 
 Acquisitions may use significant resources, may be unsuccessful, and 
      could expose us to unforeseen liabilities; 
 
 
   -- 
 Our exposure to additional risk due to our reliance on third parties in 
      many aspects of our business; 
 
 
   -- 
 Compliance with applicable laws regarding the corporate practice of 
      medicine and therapy and fee-splitting; 
 
 
   -- 
 Our facilities are subject to extensive federal and state laws and 
      regulations relating to the privacy of individually identifiable 
      information; 
 
 
   -- 
 Compliance with applicable data interoperability and information 
      blocking rule; 
 
 
   -- 
 Facility licensure requirements in some states are costly and 
      time-consuming, limiting or delaying our operations; 
 
 
   -- 
 Our ability to adequately protect and enforce our intellectual property 
      and other proprietary rights; 
 
 
   -- 
 Adverse economic conditions in the U.S. or globally; 
 
 
   -- 
 Any negative impact on the global economy and capital markets resulting 
      from other geopolitical tensions; 
 
 
   -- 
 The impact of impairment of our goodwill and other intangible assets; 
 
 
   -- 
 Our ability to maintain satisfactory credit ratings; 
 
 
   -- 
 The effects of the Separation on our business; 
 
 
   -- 
 Our ability to achieve the expected benefits of and successfully 
      execute the Separation and related transactions; 
 
 
   -- 
 Restrictions on our business, potential tax and indemnification 
      liabilities and substantial charges in connection with the Separation and 
      related transactions; 
 
 
   -- 
 The negative impact of public threats such as a global pandemic or 
      widespread outbreak of an infectious disease similar to the COVID-19 
      pandemic; 
 
 
   -- 
 The loss of key members of our management team; 
 
 
   -- 
 Our ability to attract and retain talented, highly skilled employees 
      and a diverse workforce, and on the succession of our senior management; 
 
 
   -- 
 Climate change, or legal, regulatory or market measures to address 
      climate change; 
 
 
   -- 
 Increasing scrutiny and rapidly evolving expectations from stakeholders 
      regarding ESG matters; and 
 
 
   -- 
 Changes in tax laws or exposures to additional tax liabilities. 
 

Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements, whether as a result of any new information, future events, or otherwise. You should not place undue reliance on our forward-looking statements. Although we believe that the expectations reflected in forward-looking statements are reasonable, we cannot guarantee future results or performance.

 
I. Consolidated Statements of Operations 
For the Fourth Quarters Ended December 31, 2024 and 2023 
(In thousands, except per share amounts, unaudited) 
 
                          Quarter Ended December 31, 
                        ------------------------------ 
                                   2024          2023    % Change 
                            -----------    ----------   ---------- 
Revenue                  $      465,041   $   440,740      5.5% 
                            -----------    ----------   ------ 
Costs and expenses: 
   Cost of services, 
    exclusive of 
    depreciation and 
    amortization                344,851       330,923      4.2 
   General and 
    administrative, 
    exclusive of 
    depreciation and 
    amortization(1)              45,493        42,101      8.1 
   Depreciation and 
    amortization                 15,610        18,499    (15.6) 
                            -----------    ----------   ------ 
      Total costs and 
       expenses                 405,954       391,523      3.7 
   Other operating 
   income                            --            99      N/M 
                            -----------    ----------   ------ 
Income from operations           59,087        49,316     19.8 
Other income and 
expense: 
Interest expense on 
 related party debt                  --       (10,422)     N/M 
   Interest expense             (26,439)         (113)     N/M 
   Other expense                     --            (2)     N/M 
                            -----------    ----------   ------ 
Income before income 
 taxes                           32,648        38,779    (15.8) 
   Income tax expense             9,848         9,923     (0.8) 
                            -----------    ----------   ------ 
Net income                       22,800        28,856    (21.0) 
   Less: net income 
    attributable to 
    non-controlling 
    interests                     1,288         1,021     26.2 
                            -----------    ----------   ------ 
Net income 
 attributable to the 
 Company                 $       21,512   $    27,835    (22.7)% 
                            ===========    ==========   ====== 
Basic and diluted 
 earnings per common 
 share(2)                $         0.17   $      0.27 
 

_______________________________________________________________________________

 
(1)    Includes the transaction services agreement fee of $3.7 million for the 
       fourth quarter ended December 31, 2024 and the shared service fee from 
       related party of $3.6 million for the fourth quarter ended December 31, 
       2023. 
(2)    Refer to table III for calculation of earnings per common share. 
N/M    Not meaningful 
 
 
II. Consolidated Statements of Operations 
For the Years Ended December 31, 2024 and 2023 
(In thousands, except per share amounts, unaudited) 
 
                             Year Ended December 31, 
                           --------------------------- 
                                    2024         2023    % Change 
                               ---------    ---------   ---------- 
Revenue                     $  1,900,192   $1,838,081      3.4% 
                               ---------    ---------   ------ 
Costs and expenses: 
   Cost of services, 
    exclusive of 
    depreciation and 
    amortization               1,372,217    1,325,649      3.5 
   General and 
    administrative, 
    exclusive of 
    depreciation and 
    amortization(1)              156,318      151,999      2.8 
   Depreciation and 
    amortization                  67,178       73,051     (8.0) 
                               ---------    ---------   ------ 
      Total costs and 
       expenses                1,595,713    1,550,699      2.9 
Other operating income               284          250     13.6 
                               ---------    ---------   ------ 
Income from operations           304,763      287,632      6.0 
Other income and 
expense: 
   Equity in losses of 
    unconsolidated 
    subsidiaries                  (3,676)        (526)   598.9 
   Interest expense on 
    related party debt           (21,980)     (44,253)     N/M 
   Interest expense              (47,714)        (221)     N/M 
   Other expense                      --           (2)     N/M 
                               ---------    ---------   ------ 
Income before income 
 taxes                           231,393      242,630     (4.6) 
   Income tax expense             59,496       57,887      2.8 
                               ---------    ---------   ------ 
Net income                       171,897      184,743     (7.0) 
   Less: net income 
    attributable to 
    non-controlling 
    interests                      5,354        4,796     11.6 
                               ---------    ---------   ------ 
Net income attributable 
 to the Company             $    166,543   $  179,947     (7.4)% 
                               =========    =========   ====== 
Basic and diluted 
 earnings per common 
 share(2)                   $       1.46   $     1.73 
 

(MORE TO FOLLOW) Dow Jones Newswires

March 03, 2025 16:30 ET (21:30 GMT)